US Patent

US10039780 — Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Method of Use · Assigned to Chiesi Farmaceutici SpA · Expires 2035-07-10 · 9y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical formulations containing high purity cangrelor and methods for preparing and using them to inhibit platelet activation and aggregation.

USPTO Abstract

The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Drugs covered by this patent

Kengreal (CANGRELOR) · Chiesi

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2260`	—	Kengreal

Patent Metadata

Patent number: US10039780
Jurisdiction: US
Classification: Method of Use
Expires: 2035-07-10
Drug substance claim: No
Drug product claim: No
Assignee: Chiesi Farmaceutici SpA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.